In 2020, Cures Within Reach funded Dr. Angela Fleischman at the University of California, Irvine to support a Phase I/II trial testing an FDA-approved drug, N-Acetylcysteine, as a treatment for myeloproliferative neoplasm (MPNs), a group of blood cancers including polycythemia vera, essential thrombocythemia and myelofibrosis that cause blood clots and chronic inflammation.

She has received awards for her contributions to hematology and oncology, including the MPN Challenge Award, V Foundation Scholar Award, MPN Hero Award, and the 2021 Samueli Scholar Award.

Dr. Fleischman's dedication to solving MPNs traces back to her days as a PhD student at Stanford University. She now leads an independent laboratory group dedicated to MPNs, driven by a vision where cancer is not just treated, but prevented altogether. Her overall goal: to identify what drives MPN disease initiation and to use this knowledge to develop therapies to treat or prevent this devastating disease. Dr. Fleischman hopes that someday “we will prevent, not treat, cancer.”

This Phase I/II clinical trial is investigating N-acetylcysteine to reduce symptoms and blood clotting in MPN patients. Dr. Fleischman and this trial represent three of Cures Within Reach’s communities: • Rare diseases • Oncology • Health Equity

Cures Within Reach is testing already approved treatments for unsolved diseases: driving more treatments to more patients more quickly

www.cureswithinreach.org 847.745.1252 info@cureswithinreach.org

Cures Within Reach is a 501(c)3 tax-exempt organization